Archive for November 2019
Tech firm skips Boston, chooses North Carolina for 400-job operation
Healthcare IT firm Well Dot Inc has picked Chapel Hill’s Franklin Street over Boston for a 400-job, $3.1 million operation. Read More
Read MoreJLL’s former capital markets head joins Colliers
Prior to JLL, Frank Petz served as director of capital markets at Eastdil Secured and CBRE. Read More
Read MoreTJX buys $225M stake in Russian discount retailer
The Framingham-based parent company of T.J. Maxx and Marshalls acquired a 25 percent stake in Russian retailer Familia. Read More
Read MoreA year after the state’s first two marijuana shops, a mostly warm buzz
“It’s been one year and I think the experience has been positive for Northampton overall,” said Northampton Mayor David Narkewicz. “We’ve had no major issues, no major uptick in crime." Read More
Read MoreNew York grants cryptocurrency license to Fidelity Investments
Fidelity Investments’ digital-currency business won state regulatory approval to operate in New York. Read More
Read MoreVerizon’s 5G network debuts in Fenway
The company is following up on its promise to bring 5G to mobile customers in more cities — including Boston — by the end of the year. Read More
Read MoreFidelity continues to buy into Larry Culp’s vision for GE
In Culp’s first year as GE CEO, the money manager more than tripled its stake in the Boston-based conglomerate. Read More
Read MoreCompromise bill calls for $1.5B in new education spending
House and Senate negotiators filed a compromise bill that would change the course of state K-12 education funding over the next seven years. Read More
Read MoreCRISPR Therapeutics stock jumps on early gene editing data
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia. Read More
Read MoreWill Deval Patrick’s ties to drug companies help or hurt his 2020 bid?
Serving on the board of a South San Francisco company on the cusp of a drug approval may have helped this Democratic Party candidate for president gain insight into drug pricing. It also may make him a target for other candidates. Read More
Read More